Across TCGA pan-cancer cohorts, MIR181D RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MIR181D’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where MIR181D RNA is repressed in tumor relative to normal tissue. In most cancer types MIR181D is over-expressed in tumor, although a few such as LUSC and BRCA show the opposite, repressed pattern.

LUSC, BRCA, and HNSC are the cancer types where MIR181D tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MIR181D RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUSC	All	All	−0.179	.002	4	view →
BRCA	All	All	−0.169	.003	4	view →
HNSC	All	II,III,IV	+0.084	.023	3	view →
UCEC	All	All	−0.266	.045	2	view →
COAD	All	All	+0.234	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MIR181D RNA expression & survival · all MIR181D data types